Literature DB >> 27629069

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course.

François Raffi1, Vincent Le Moing2, Alex Assuied3, Sofiane Habak4, Bruno Spire5, Charles Cazanave6, Eric Billaud7, Pierre Dellamonica8, Tristan Ferry9, Catherine Fagard3, Catherine Leport4,10.   

Abstract

OBJECTIVES: We assessed factors, including treatment course, associated with failure to obtain a 10 year immunological response after starting first-generation PI-containing combined ART (cART). PATIENTS AND METHODS: In the prospective COPILOTE cohort of HIV-infected patients started on a first-generation PI-containing regimen in 1997-99, the impact of cART history on the failure to achieve immunological response measured at 10 years was assessed by multivariate logistic regression models in the 399 patients with clinical and virological success of cART.
RESULTS: Failure of CD4 response (CD4 >500/mm3) was associated with age ≥40 years at baseline (P < 0.001), CD4 cell counts ≤500/mm3 at month 4 (P = 0.016) or month 12 (P < 0.001) and ≥3 months of cART interruption (P = 0.016). Factors associated with failure to achieve complete immunological response (CD4 >500/mm3 and CD4:CD8 ratio >1) were CD4:CD8 ratio ≤0.8 at month 8 (P < 0.001) or month 12 (P < 0.001), ≥3 months of cumulative cART interruption (P = 0.011), ≥3 antiretroviral regimens (P = 0.009) and ≤4 treatment lines (P = 0.015). Baseline CD4 and CD4:CD8 ratio were not predictors of the 10 year immunological outcomes.
CONCLUSIONS: In this therapeutic cohort of patients starting first-generation PI-containing cART in 1997-99, poor initial immunological response had a negative impact on 10 year CD4 and CD4 plus CD4:CD8 ratio response, despite prolonged virological success. Lack of treatment interruption may improve long-term immunological outcome in HIV infection.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27629069     DOI: 10.1093/jac/dkw369

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; Oksana Zakharova; JoAnn Kuruc; Cynthia Gay; Charles B Hicks; Kara S Mcgee; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

2.  Sex disparities in outcomes among adults on long-term antiretroviral treatment in northern Nigeria.

Authors:  Baba M Musa; Musa A Garbati; Ibrahim M Nashabaru; Shehu M Yusuf; Aisha M Nalado; Daiyabu A Ibrahim; Melynda N Simmons; Muktar H Aliyu
Journal:  Int Health       Date:  2016-12-09       Impact factor: 2.473

3.  Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.

Authors:  Milosz Parczewski; Ewa Siwak; Magdalena Leszczyszyn-Pynka; Iwona Cielniak; Ewa Burkacka; Piotr Pulik; Adam Witor; Karolina Muller; Ewelina Zasik; Anna Grzeszczuk; Maria Jankowska; Małgorzata Lemańska; Anita Olczak; Edyta Grąbczewska; Aleksandra Szymczak; Jacek Gąsiorowski; Bartosz Szetela; Monika Bociąga-Jasik; Paweł Skwara; Magdalena Witak-Jędra; Elżbieta Jabłonowska; Kamila Wójcik-Cichy; Juliusz Kamerys; Małgorzata Janczarek; Dagny Krankowska; Tomasz Mikuła; Katarzyna Kozieł; Dariusz Bielec; Justyna Stempkowska; Aleksandra Kocbach; Wiesława Błudzin; Andrzej Horban
Journal:  J Int AIDS Soc       Date:  2017-07-17       Impact factor: 5.396

4.  Stockouts of HIV commodities in public health facilities in Kinshasa: Barriers to end HIV.

Authors:  Tinne Gils; Claire Bossard; Kristien Verdonck; Philip Owiti; Ilse Casteels; Maria Mashako; Gilles Van Cutsem; Tom Ellman
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

5.  Immunological failure in HIV-infected adults from 2003 to 2015 in Southwest Ethiopia: a retrospective cohort study.

Authors:  Hailay Abrha Gesesew; Paul Ward; Kifle Woldemichael; Lillian Mwanri
Journal:  BMJ Open       Date:  2018-08-17       Impact factor: 2.692

6.  Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia.

Authors:  Gizachew Ayele; Belay Tessema; Anteneh Amsalu; Getachew Ferede; Gizachew Yismaw
Journal:  BMC Immunol       Date:  2018-12-17       Impact factor: 3.615

7.  The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China.

Authors:  Chong-Xi Li; Yu-Ye Li; Li-Ping He; Jing Kou; Jin-Song Bai; Jun Liu; Bo Tian; Li-Juan Cao; Kun-Hua Wang; Yi-Qun Kuang
Journal:  BMC Immunol       Date:  2019-08-28       Impact factor: 3.615

8.  The effect of tuberculosis on immune reconstitution among HIV patients on highly active antiretroviral therapy in Adigrat general hospital, eastern Tigrai, Ethiopia; 2019: a retrospective follow up study.

Authors:  Hadush Negash; Haftom Legese; Mebrahtu Tefera; Fitsum Mardu; Kebede Tesfay; Senait Gebresilasie; Berhane Fseha; Tsega Kahsay; Aderajew Gebrewahd; Brhane Berhe
Journal:  BMC Immunol       Date:  2019-12-05       Impact factor: 3.615

9.  Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia.

Authors:  Genet Gebrehiwet Hailu; Dawit Gebregziabher Hagos; Amlsha Kahsay Hagos; Araya Gebreyesus Wasihun; Tsehaye Asmelash Dejene
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

10.  A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach.

Authors:  Emiliano Mancini; Rick Quax; Andrea De Luca; Sarah Fidler; Wolfgang Stohr; Peter M A Sloot
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.